Orion OYJ (OTCMKTS:ORINY) Hits New 1-Year High - Here's What Happened

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $37.81 and last traded at $37.81, with a volume of 106 shares traded. The stock had previously closed at $37.18.

Orion OYJ Stock Down 0.7%

The company has a market cap of $11.04 billion, a P/E ratio of 29.85 and a beta of 0.10. The stock's 50-day moving average price is $34.72 and its 200-day moving average price is $29.83. The company has a current ratio of 3.79, a quick ratio of 2.27 and a debt-to-equity ratio of 0.27.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $373.03 million for the quarter. Orion OYJ had a net margin of 21.74% and a return on equity of 36.23%. As a group, research analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current year.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.